PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
October 1, 2026
Biotechnology
-
-
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
September 29, 2026
-
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
September 22, 2026
-
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus(TM)
September 15, 2026
-
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
September 15, 2026
-
Evaxion applies its AI-Immunology(TM) platform in autoimmune diseases
September 14, 2026
-
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026
-
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
September 11, 2026
-
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical’s FDA-Cleared Robotic TMS System
September 11, 2026
-
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol “EOCN” to Reflect its New Dawn Platform for GI Innovation
September 9, 2026
-
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
September 4, 2026
-
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 3, 2026
-
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
September 1, 2026
-
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 1, 2026
-
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
August 31, 2026
-
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
August 28, 2026